Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Dolman

Showing results (151-160 of 165) with videos related to

Pageof 17
Sort By:
Rheumatology (Oxford, England)|December 26, 2012
Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Marieke H Otten, Femke H M Prince, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterMarieke H Otten, Femke H M Prince, Janneke Anink, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterMarieke H Otten, Janneke Anink, Femke H M Prince, et al.
Cancer Cytopathology|May 27, 2021
The important role of routine cytopathology in pediatric precision oncologyJinhan Xie, Amit Kumar, M Emmy M Dolman, et al.
Rheumatology (Oxford, England)|June 7, 2013
Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?Janneke Anink, Marieke H Otten, Simone L Gorter, et al.
Molecular Systems Biology|October 1, 2025
High-throughput 3D engineered paediatric tumour models for precision medicineMoonSun Jung, Valentina Poltavets, Joanna N Skhinas, et al.
Nature Communications|May 19, 2026
Precision-guided therapy in H3K27-altered diffuse midline gliomaCampbell J L McKay, Chelsea Mayoh, Phoebe Power, et al.
Nature Communications|November 20, 2018
TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targetsBieke Decaesteker, Geertrui Denecker, Christophe Van Neste, et al.
Cancer Research|July 31, 2023
High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk CancerChelsea Mayoh, Jie Mao, Jinhan Xie, et al.
Molecular Cancer Therapeutics|March 18, 2026
Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across sarcomas affecting the youngAshleigh M Fordham, Lauren M Brown, Chelsea Mayoh, et al.
Pageof 17

Showing results (151-160 of 165) with videos related to

Sort By:
Pageof 17
Rheumatology (Oxford, England)|December 26, 2012
Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Marieke H Otten, Femke H M Prince, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterMarieke H Otten, Femke H M Prince, Janneke Anink, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterMarieke H Otten, Janneke Anink, Femke H M Prince, et al.
Cancer Cytopathology|May 27, 2021
The important role of routine cytopathology in pediatric precision oncologyJinhan Xie, Amit Kumar, M Emmy M Dolman, et al.
Rheumatology (Oxford, England)|June 7, 2013
Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?Janneke Anink, Marieke H Otten, Simone L Gorter, et al.
Molecular Systems Biology|October 1, 2025
High-throughput 3D engineered paediatric tumour models for precision medicineMoonSun Jung, Valentina Poltavets, Joanna N Skhinas, et al.
Nature Communications|May 19, 2026
Precision-guided therapy in H3K27-altered diffuse midline gliomaCampbell J L McKay, Chelsea Mayoh, Phoebe Power, et al.
Nature Communications|November 20, 2018
TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targetsBieke Decaesteker, Geertrui Denecker, Christophe Van Neste, et al.
Cancer Research|July 31, 2023
High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk CancerChelsea Mayoh, Jie Mao, Jinhan Xie, et al.
Molecular Cancer Therapeutics|March 18, 2026
Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across sarcomas affecting the youngAshleigh M Fordham, Lauren M Brown, Chelsea Mayoh, et al.
Pageof 17